MedPointe To Seek Fluorofelbamate Partner After Carter-Wallace Acquisition
Executive Summary
MedPointe will likely seek a development partner for the anti-epileptic fluorofelbamate after the company acquires Carter-Wallace's healthcare business.
You may also be interested in...
Soma Tablet Particles Show No Adverse Health Effects, MedPointe Tells FDA
MedPointe expects to address FDA's Soma manufacturing concerns with a final report showing no adverse health effects from black specks found on carisoprodol tablets
Soma Tablet Particles Show No Adverse Health Effects, MedPointe Tells FDA
MedPointe expects to address FDA's Soma manufacturing concerns with a final report showing no adverse health effects from black specks found on carisoprodol tablets
Carter-Wallace Felbatol (correction)
Carter-Wallace's Felbatol (felbamate) is restricted to second-line use in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children due to risk of aplastic anemia and liver failure. "The Pink Sheet" (Aug. 27, p. 29) incorrectly reported that Felbatol had been withdrawn